clinicaltrials.gov
RSS kanal za ClinicalTrials.gov: Other terms: ("generalized myasthenia gravis" OR "myasthenia gravis") AND (eculizumab OR ravulizumab OR gefurulimab OR inebilizumab OR nipocalimab OR zilucoplan OR rozanolixizumab OR efgartigimod OR remibrutinib) | Last update posted
Primaj najnovije objave od ClinicalTrials.gov: Other terms: ("generalized myasthenia gravis" OR "myasthenia gravis") AND (eculizumab OR ravulizumab OR gefurulimab OR inebilizumab OR nipocalimab OR zilucoplan OR rozanolixizumab OR efgartigimod OR remibrutinib) | Last update posted odmah čim se pojave.
Najnovije objave
Čitajte ClinicalTrials.gov: Other terms: ("generalized myasthenia gravis" OR "myasthenia gravis") AND (eculizumab OR ravulizumab OR gefurulimab OR inebilizumab OR nipocalimab OR zilucoplan OR rozanolixizumab OR efgartigimod OR remibrutinib) | Last update posted tamo gdje inače čitate
Pitanja
Koji je URL RSS kanala za ClinicalTrials.gov: Other terms: ("generalized myasthenia gravis" OR "myasthenia gravis") AND (eculizumab OR ravulizumab OR gefurulimab OR inebilizumab OR nipocalimab OR zilucoplan OR rozanolixizumab OR efgartigimod OR remibrutinib) | Last update posted?
Adresa RSS kanala je https://clinicaltrials.gov/api/rss?term=%28%22generalized+myasthenia+gravis%22+OR+%22myasthenia+gravis%22%29+AND+%28eculizumab+OR+ravulizumab+OR+gefurulimab+OR+inebilizumab+OR+nipocalimab+OR+zilucoplan+OR+rozanolixizumab+OR+efgartigimod+OR+remibrutinib%29&dateField=LastUpdatePostDate. Zalijepite je u bilo koji RSS čitač ili kliknite Prati odmah da biste ga čitali u aplikaciji Feeder.
Koliko često ClinicalTrials.gov: Other terms: ("generalized myasthenia gravis" OR "myasthenia gravis") AND (eculizumab OR ravulizumab OR gefurulimab OR inebilizumab OR nipocalimab OR zilucoplan OR rozanolixizumab OR efgartigimod OR remibrutinib) | Last update posted objavljuje?
ClinicalTrials.gov: Other terms: ("generalized myasthenia gravis" OR "myasthenia gravis") AND (eculizumab OR ravulizumab OR gefurulimab OR inebilizumab OR nipocalimab OR zilucoplan OR rozanolixizumab OR efgartigimod OR remibrutinib) | Last update posted objavljuje oko 5 puta tjedno. Posljednja objava bila je prije 5 dana.
Radi li RSS kanal za ClinicalTrials.gov: Other terms: ("generalized myasthenia gravis" OR "myasthenia gravis") AND (eculizumab OR ravulizumab OR gefurulimab OR inebilizumab OR nipocalimab OR zilucoplan OR rozanolixizumab OR efgartigimod OR remibrutinib) | Last update posted?
Da. Feeder ga je provjerio prije 4 minute, a RSS kanal odgovorio je normalno.
Kako pratiti ClinicalTrials.gov: Other terms: ("generalized myasthenia gravis" OR "myasthenia gravis") AND (eculizumab OR ravulizumab OR gefurulimab OR inebilizumab OR nipocalimab OR zilucoplan OR rozanolixizumab OR efgartigimod OR remibrutinib) | Last update posted u aplikaciji Feeder?
Kliknite Prati odmah i registrirajte se ako još nemate račun. Feederov besplatni plan obuhvaća do 200 izvora na webu, iPhoneu i Androidu. Kreditna kartica nije potrebna.
Pratite ClinicalTrials.gov: Other terms: ("generalized myasthenia gravis" OR "myasthenia gravis") AND (eculizumab OR ravulizumab OR gefurulimab OR inebilizumab OR nipocalimab OR zilucoplan OR rozanolixizumab OR efgartigimod OR remibrutinib) | Last update posted u Feederu
Feederov besplatni plan obuhvaća do 200 izvora na webu, iPhoneu i Androidu. Kreditna kartica nije potrebna.